In this video, Dr. Jean Zenklusen describes an NCI tool that enables researchers, clinicians, and patients to access an array of cancer-related data.
In this video, Dr. Douglas Fearon outlines ways that inhibiting CXCR4 may provoke an immune response to treat pancreatic and colorectal cancer.
In this video, Dr. Patricia Steeg discusses the role of the blood-tumor barrier in both development and treatment of brain metastases.
In this video, Dr. Arman Rahman explains how the OncoMasTR protein assay may help women with breast cancer avoid unnecessary chemotherapy.
Combining mitoxantrone and prednisone with adjuvant androgen deprivation therapy failed to improve overall survival over ADT alone in patients with high-risk prostate cancer.
Previous studies found calcium channel blockers could prevent pancreatic cancer, but have neglected to consider the effects of short-acting CCBs.
At AACR 2018, Dr. Aung Naing of MD Anderson presented ECHO-203, the first data on epacadostat in combination with an anti–PD-L1 inhibitor.
Stage III colon cancer patients adhering to ACS Nutrition and Physical Activity Guidelines for Cancer Survivors after diagnosis had a 42% lower risk of death.
A biomarker known as RAD51 was found to be correlated with resistance to PARP inhibitor treatment in a study of breast cancer that harbors BRCA mutations.
Antibiotics administered within 30 days of starting immunotherapy reduced both PFS and OS for patients with advanced RCC and NSCLC.